ArticleTranslational andrology and urology2025
Clinical outcomes of modified partial cystectomy in muscle-invasive bladder cancer: balancing tumor control and quality of life.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Muscle-invasive bladder cancer (MIBC) is highly aggressive with poor prognosis. Radical cystectomy (RC) with urinary diversion, the standard treatment, impairs patients' quality of life. This study explored modified partial cystectomy (MPC) as a bladder-preserving option, assessing oncological control, perioperative outcomes, and quality of life. Methods: Patients who underwent partial cystectomy for urothelial carcinoma at the Affiliated Cancer Hospital of Guangzhou Medical University between January 2020 and January 2022 were included. Some received standard laparoscopic partial cystectomy (LPC), while others received MPC with laparoscopic pelvic lymph node dissection and open tumor resection. These were compared with a gold standard group undergoing RC and lymph node dissection, evaluating perioperative, functional, and oncological outcomes. Results: Among the 57 patients (16 MPC, 18 LPC, 23 RC), LPC patients were older, RC tumors were more commonly located on the trigone, and tumors in the RC group were larger. Major complications were 21.7% in RC, Conclusions: MPC surpasses LPC in tumor resection, reducing recurrence and enhancing survival. MPC also achieves similar oncological results to RC, making it a promising bladder-preserving alternative for MIBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.